Vivibaba specializes in protein delivery and advanced formulation of protein therapeutics.


Compared with small molecular drugs, protein therapeutics generally show higher specificity and potency. Broad adaption of protein therapeutics, however, has been limited by undesired stability, immunogenicity and pharmacokinetics, as well as the inability to penetrate through the brain blood barrier (BBB). Nevertheless, the global market for protein therapeutics represented $171 billion in 2019 is expected to grow at a rate of 2-8% over the next ten years.


Vivibaba has developed a platform technology based on single-protein nanocapsules, which enables protein delivery with enhanced stability, reduced immunogenicity, prolonged circulation time, controlled release and targeting capability. Particularly, Vivibaba's technology can penetrate the BBB, enabling effective delivery of therapeutic proteins including nerve growth factors and monoclonal antibodies to the central nerve system (CNS) for neurodegeneration diseases, primary and metastatic brain cancer, spinal cord injury, and other diseases.


  • Enhanced protein stability
  • Prolonged half life
  • Reduced immunogenicity
  • Controlled release and targeting capability
  • Blood Brain Barrier (BBB) penetrative capability

Development Stage:

  • Pre-clinical

Patents Pending:

  • “Single protein nanocapsules for protein delivery with long-term effect”, PCT WO2010104865
  • “Stealth nanocapsules for protein delivery”, PCT WO2016085808

Select Publications:

Graduated in 2020

Back to Top